New treatment options for infections caused by drug-resistant bacteria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of various combination therapies for treating infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) in ICU patients. Participants will receive one of three treatment regimens involving colistin combined with either fosfomycin, ampicillin/sulbactam, or eravacycline. The primary goal is to achieve negative culture results after 10 days of therapy, while secondary objectives include assessing survival rates, ICU discharge, and reduction in infection severity. The study will also monitor patient-specific factors to tailor individual treatment plans.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Surgical patients (abdominal, vascular, and polytraumatized patients)
* Older than 18 years
* Require postoperative treatment in the ICU
* A positive sample (surveillance or diagnostic) for A. baumannii with signs of systemic infection

Infection will be defined as a diagnostic microbiologically positive sample for A. baumannii and a surveillance microbiologically positive sample for A. baumannii with signs of systemic infection (elevated CRP, leukocytes, and body temperature).

Colonization will be defined as a positive surveillance microbiological sample for A. baumannii in the absence of signs of systemic infection (normal CRP, leukocytes, and body temperature).

Exclusion Criteria:

* Allergy to the study medications
* Positive surveillance swabs for A. baumannii without signs of systemic infection
* Positive findings (surveillance or diagnostic) for carbapenem-sensitive A. baumannii
* Refusal to participate in the research

Where it's running

• University Hospital Centre Zagreb
  Zagreb, Croatia Recruiting

Study contacts

• Principal investigator: Ivan Šitum — UHC Zagreb
• Study coordinator: Ivan Šitum
• Email: ivsitum@gmail.com
• Phone: 0915143620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GRADY: a computer tool to detect early sepsis and gram-negative bloodstream infection in ICU patients

  The GRADY tool will be tested to see if routine vital signs and lab results can detect early sepsis and gram-negative bloodstream infection in adult ICU patients.

  Recruiting Sisli Hamidiye Etfal Training and Research Hospital · Seyrantepe, Istanbul · NCT07126106

• Blood-based metagenomic sequencing to find infections in immunocompromised adults

  We will test whether adding the Karius Spectrum blood test to usual diagnostic care helps doctors find and treat infections faster in immunocompromised adults evaluated as outpatients.

  Recruiting at 4 sites Karius, Inc. · San Francisco, California and 5 other locations · NCT07110636

• Early versus late stopping of antibiotics for adults with high‑risk blood cancers or after stem‑cell or CAR T therapy who develop fever

  This trial tests if stopping antibiotics early is safe for adults with leukemia or after stem‑cell transplant or CAR T therapy when a fever has settled.

  Recruiting at 2 sites Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria and 1 other locations · NCT07051525

• Evaluating antibiotic effectiveness in patients with infections

  This study is testing how well beta-lactam antibiotics work for patients with infections by checking if they get the right amount of the medicine in their system to help them recover.

  Recruiting Imperial College London · London · NCT06427317

• Molecular culture for diagnosing sepsis in children

  This study is testing a faster way to diagnose sepsis in newborns and children by using a new blood test to see if it can identify infections more quickly than the usual method.

  Recruiting at 2 sites Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam and 1 other locations · NCT06018792

• CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection

  This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.

  Recruiting Phase 1 Centauri Therapeutics Limited · Groningen · NCT07708116

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.